Daxor Settles Lawsuits with the New York State Department of Health.NEW YORK--(BUSINESS WIRE)--Nov. 3, 1998--The Daxor Corporation and a representative of the New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of State Health Department (NYSDOH NYSDOH New York State Department of Health ) signed an agreement today to settle a number of lawsuits which date back almost ten years. The agreement calls for the establishment of a separate subsidiary for the operation of Daxor's New York semen semen or seminal fluid Whitish viscous fluid emitted from the male reproductive tract that contains sperm and liquids (seminal plasma) that help keep them viable. bank and long term frozen storage blood bank with a separate Board of Directors. Daxor's semen bank is the only semen bank in the State of New York accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the America Association of Tissue Banks (AATB AATB American Association of Tissue Banks AATB All About the Benjamins (TV show) AATB Alto Alto Tenor Baritone (sax quartet) AATB Army Arctic Test Board (Fort Greely, AK) ). The disputes involve multiple issues which have been described in previous releases. The president of Daxor Corp., Dr. Joseph Feldschuh, stated he believes that this agreement will provide an historic turning point and a new and positive relationship between Daxor and the NYSDOH. The company believes that it is fortunate that these specialized services will be available to members of the public. The Daxor Corporation's main focus will involve the advancement and distribution of the company's Blood Volume Analyzer (BVA-100). The company recently acquired a manufacturing facility in New York State for the production of the specialized syringe used as part of the Blood Volume Analyzer injection kit. The company is currently involved in beta-testing its Blood Volume Analyzer in various hospitals. The BVA-100 is the first instrument to provide rapid blood volume measurement in humans. Results can be obtained within 18-35 minutes. This permits results to be available to physicians in situations where critical decisions in regard to fluid and blood transfusion blood transfusion, transfer of blood from one person to another, or from one animal to another of the same species. Transfusions are performed to replace a substantial loss of blood and as supportive treatment in certain diseases and blood disorders. therapy must be made. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion